Eli Lilly Acquires Kelonia Therapeutics for $7 Billion, Bolstering Gene Therapy with In Vivo CAR-T Generation Technology

July 26, 2026

DCAT Value Chain Insights USA

Overview

Eli Lilly announced the acquisition of Kelonia Therapeutics, a clinical-stage biopharma specializing in in vivo gene delivery, for $7 billion, including $3.25 billion upfront. Kelonia’s “iGPS” technology utilizes lentivirus-based particles to generate CAR T-cells directly within the body, potentially simplifying CAR-T manufacturing and administration. This substantial investment underscores Lilly’s commitment to gene therapy and the commercialization potential of next-generation cell therapies.

In Depth

Key Findings

Pharmaceutical giant Eli Lilly and Company has announced the acquisition of Kelonia Therapeutics, a clinical-stage biopharmaceutical company focused on in vivo gene delivery, for an aggregate of $7 billion. This landmark deal includes an upfront payment of $3.25 billion and an additional $3.75 billion in milestone payments, signaling a significant strategic move by Eli Lilly to expand its footprint in the rapidly evolving cell and gene therapy landscape, particularly with an innovative in vivo CAR-T cell approach.

Technical and Clinical Details

Kelonia Therapeutics’ core technology is its in vivo Gene Placement System (iGPS), designed to enable the direct generation of CAR T-cells within a patient’s body. The iGPS platform employs specially engineered lentivirus-based particles that program T-cells to express CAR-T receptors in situ. This method offers a distinct advantage over conventional ex vivo CAR-T therapies by circumventing the complex, costly, and time-consuming processes of cell extraction, external manufacturing, and reinfusion. The potential benefits include reduced manufacturing costs, shorter vein-to-vein time, and broader patient accessibility. While Kelonia’s pipeline is in early clinical stages, the in vivo approach directly addresses a major challenge in gene therapy delivery.

Background & Context

CAR-T cell therapies have revolutionized the treatment of hematological malignancies but are hampered by high production costs, intricate supply chains, and limited patient access. In vivo gene delivery represents a promising solution to these challenges, with the ability to generate therapeutic cells directly within the patient holding the potential to transform the cell therapy paradigm. The substantial investment by a major pharmaceutical player like Eli Lilly into an early-stage, innovative in vivo technology underscores the industry’s strong conviction in its disruptive potential. This acquisition reflects the accelerating maturation of the gene therapy market through significant M&A activities.

Strategic Significance & Outlook

Eli Lilly’s acquisition of Kelonia demonstrates its clear intent to establish leadership in the gene therapy space. Moving forward, the industry will closely watch how Kelonia’s iGPS technology is deployed across various disease areas, particularly in solid tumors and autoimmune diseases—the next frontiers for CAR-T therapies. Crucial factors for the success of this acquisition will include the validation of the in vivo gene delivery technology’s safety and long-term efficacy, alongside further optimization of the manufacturing process. This acquisition marks a pivotal step towards a future where cell and gene therapies become more accessible and cost-effective treatment options.

Source: https://www.dcatvci.org/features/in-vivo-cell-therapies-solving-mfg-obstacles/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.